203 related articles for article (PubMed ID: 27542768)
1. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
Kelly K; Mejia A; Suhasini AN; Lin AP; Kuhn J; Karnad AB; Weitman S; Aguiar RC
Clin Cancer Res; 2017 Mar; 23(5):1186-1192. PubMed ID: 27542768
[No Abstract] [Full Text] [Related]
2. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
[TBL] [Abstract][Full Text] [Related]
3. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
Blokland A; Van Duinen MA; Sambeth A; Heckman PRA; Tsai M; Lahu G; Uz T; Prickaerts J
Neurobiol Aging; 2019 May; 77():37-43. PubMed ID: 30776650
[TBL] [Abstract][Full Text] [Related]
4. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
[TBL] [Abstract][Full Text] [Related]
5. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
7. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Rogliani P; Calzetta L; Cazzola M; Matera MG
Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
9. If roflumilast inhibits the innate immunity in the stable patient, what about infection?
Blasco LM
Clin Respir J; 2013 Jan; 7(1):e11-2. PubMed ID: 22364166
[No Abstract] [Full Text] [Related]
10. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
[TBL] [Abstract][Full Text] [Related]
11. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
Eckermann G; Lahu G; Nassr N; Bethke TD
J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
[TBL] [Abstract][Full Text] [Related]
12. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
Park TS; Kang J; Lee JS; Oh YM; Lee SD; Lee SW
Int J Chron Obstruct Pulmon Dis; 2019; 14():871-879. PubMed ID: 31354255
[TBL] [Abstract][Full Text] [Related]
13. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
Snape SD; Wigger-Alberti W; Goehring UM
Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
[TBL] [Abstract][Full Text] [Related]
14. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
Gilleen J; Nottage J; Yakub F; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Williams SC; Ffytche D; Mehta MA; Shergill SS
J Psychopharmacol; 2021 Jan; 35(1):15-22. PubMed ID: 32854568
[TBL] [Abstract][Full Text] [Related]
15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast (Daliresp) for COPD.
Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
[No Abstract] [Full Text] [Related]
17. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
19. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
de Mey C; Nassr N; Lahu G
BMC Clin Pharmacol; 2011 Jun; 11():7. PubMed ID: 21631929
[TBL] [Abstract][Full Text] [Related]
20. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
